Synaptic vesicle protein 2 A mitigates parthanatos via apoptosis‐inducing factor in a rat model of pharmacoresistant epilepsy
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14778 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Chen Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China. Hauptthemen laut MEDLINE: Apoptosis Inducing Factor, Drug Resistant Epilepsy, Membrane Glycoproteins, Nerve Tissue Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, The Cultivation Program of the National Natural Science Foundation, The Affiliated Hospital of Guizhou Medical University, Guizhou Provincial Science and Technology Projects Qiankehe platform talent.
Abstract (Originalsprache)
Aims
Synaptic vesicle protein 2A (SV2A) is a unique therapeutic target for pharmacoresistant epilepsy (PRE). As seizure‐induced neuronal programmed death, parthanatos was rarely reported in PRE. Apoptosis‐inducing factor (AIF), which has been implicated in parthanatos, shares a common cytoprotective function with SV2A. We aimed to investigate whether parthanatos participates in PRE and is mitigated by SV2A via AIF.
Methods
An intraperitoneal injection of lithium chloride‐pilocarpine was used to establish an epileptic rat model, and phenytoin and phenobarbital sodium were utilized to select PRE and pharmacosensitive rats. The expression of SV2A was manipulated via lentivirus delivery into the hippocampus. Video surveillance was used to assess epileptic ethology. Biochemical tests were employed to test hippocampal tissues following a successful SV2A infection. Molecular dynamic calculations were used to simulate the interaction between SV2A and AIF.
Results
Parthanatos core index, PARP1, PAR, nuclear AIF and MIF, γ‐H2AX, and TUNEL staining were all increased in PRE. SV2A is bound to AIF to form a stable complex, successfully inhibiting AIF and MIF nuclear translocation and parthanatos and consequently mitigating spontaneous recurrent seizures in PRE. Moreover, parthanatos deteriorated after the SV2A reduction. Significance SV2A protected hippocampal neurons and mitigated epileptic seizures by inhibiting parthanatos via binding to AIF in PRE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
- The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
ORCID-Profile: Chen Li
Förderung
- National Natural Science Foundation of China
- The Cultivation Program of the National Natural Science Foundation, The Affiliated Hospital of Guizhou Medical University
- Guizhou Provincial Science and Technology Projects Qiankehe platform talent
Zitieren
APA
Li, C., Wang, Z., Ren, M., Ren, S., Wu, G., & Wang, L. (2024). Synaptic vesicle protein 2 A mitigates parthanatos via apoptosis‐inducing factor in a rat model of pharmacoresistant epilepsy. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14778
Vancouver
Li C, Wang Z, Ren M, Ren S, Wu G, Wang L. Synaptic vesicle protein 2 A mitigates parthanatos via apoptosis‐inducing factor in a rat model of pharmacoresistant epilepsy. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14778
BibTeX
@article{Li2024,
author = {Li, Chen and Wang, Ziqi and Ren, Mianmian and Ren, Siying and Wu, Guofeng and Wang, Likun},
title = {Synaptic vesicle protein 2 A mitigates parthanatos via apoptosis‐inducing factor in a rat model of pharmacoresistant epilepsy},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14778}
}
EUVIMED